Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 02, 2015 7:37 PM ET

Company Overview of Universite Libre de Bruxelles in Belgium

Company Overview

Universite Libre de Bruxelles in Belgium is an educational institution.



Key Executives for Universite Libre de Bruxelles in Belgium

Universite Libre de Bruxelles in Belgium does not have any Key Executives recorded.

Universite Libre de Bruxelles in Belgium Key Developments

Universite Libre de Bruxelles and ChromaDex Corporation to Collaborate on NIAGEN(TM) Nicotinamide Riboside Research

ChromaDex Corp. announced it has entered into a material transfer agreement (MTA) with Universite Libre de Bruxelles, whereby ChromaDex will provide ULB with quantities of its recently launched NIAGEN(TM) nicotinamide riboside (NR). Dr. Oberdan Leo, with the help of Drs. Fabienne Andris, Anthony Rongvaux and Frederic Van Gool at the Universite Libre de Bruxelles, identified the mammalian gene encoding for nicotinamide phosphoribosyl tranferase (Nampt), the rate limiting enzyme in the biosynthetic pathway linking nicotinamide (a major component of Vitamin B3) to NAD. The group led by Dr. Leo later demonstrated that this biosynthetic pathway plays an important role in lymphocyte development and in the regulation of innate immunity. ChromaDex's NIAGEN(TM) has the potential to be a next generation niacin (Vitamin B3) and become part of the portfolio of B-vitamin ingredients that are included in products serving multi-billion dollar markets such as multi-vitamins, nutraceuticals, weight-loss, energy drinks, sports nutrition, meal replacements, infant formula, food and beverage products. NIAGEN(TM) is the first and only commercially available brand of NR. Over the past two years, ChromaDex has built a significant patent portfolio pertaining to NR by separately acquiring patent rights from Cornell University, Dartmouth College and Washington University. ChromaDex believes its patent rights create a significant and meaningful barrier to entry for would-be competitors in the NR market.

Similar Private Companies By Industry

Company Name Region
Carrières du Hainaut S.C.A. Europe
Konstrukt-Al NV Europe
Indis NV Europe
Société Hôtelière de Bruxelles NV Europe
Deckers Sa Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Universite Libre de Bruxelles in Belgium, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at